A study in 2017 revealed that chemerin was downregulated in the bone marrow mononuclear cells of AML patients compared to that of healthy controls, with ROC curve analysis showing a test specificity of 79% (true positive) and sensitivity of 54% (true negative) for chemerin expression as a marker for AML diagnosis. Here, RARRES2 is linked to acute myeloid leukemia.